Dublin, Ohio-based Cardinal Health, Inc. (CAH) operates as a healthcare services and products company in the United States and internationally. With a market cap of $37.8 billion, the company has two reporting segments: Pharmaceutical and Medical. The company is set to release its fiscal Q4 earnings results on Tuesday, Aug. 12, before the market opens.

Ahead of the event, analysts expect CAH to report a profit of $2.03 per share, up 10.3% from $1.84 per share in the year-ago quarter. The company surpassed Wall Street’s bottom-line estimates in each of the past four quarters, which is impressive.

For the current year, analysts expect CAH to report EPS of $8.20, up 8.9% from $7.53 in fiscal 2024.

CAH stock has delivered robust gains over the past year, surging 64.6%, outpacing the S&P 500’s ($SPX) 13.4% gains and the Health Care Select Sector SPDR Fund’s (XLV) 10.2% decline over the same time frame.

On June 13, CAH stock jumped over 4%, leading other healthcare stocks after the company raised its full-year adjusted EPS guidance to $8.15 to $8.20, surpassing the previous range and beating the consensus estimate of $8.14.

The consensus opinion on CAH stock is strongly bullish, with an overall “Strong Buy” rating. Among the 14 analysts covering the stock, 11 advise a “Strong Buy” rating and three suggest “Hold.” CAH’s average analyst price target is $180.33, indicating a potential upside of 14.8% from the current price levels.